-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2021, affected by factors such as policies, valuations, and expectations, the pharmaceutical sector will undergo significant adjustments
.
In the long run, medicine is just in demand.
With the increase in per capita disposable income and the continuous upgrading of consumption, the pharmaceutical sector still has good growth potential, so it is also favored by many fund managers
.
From the perspective of trends, some pharmaceutical researchers said that the pharmaceutical and biological industry is gradually showing two major directions of diversification and segmentation
.
On the one hand, with the improvement of people's living standards, people's demand for different products in the field of pharmaceutical consumption is also increasing, making the pharmaceutical and biological industry track gradually diversified
.
For example, emerging tracks such as early intervention in diabetes, medical and cosmetic products, and intervention in ophthalmic diseases have emerged
.
China is a big country with diabetes, with a huge number of patients, up to over 100 million
.
With the enhancement of people's health awareness, they have gradually realized that diabetes prevention is more important than treatment.
On the basis of life>
.
In this context, patients are also actively seeking help and implementing diabetes management, which has driven the continuous expansion of the domestic diabetes management market and attracted companies to continue to deploy
.
In the era of beauty economy, coupled with the improvement of people's living standards, the demand for medical beauty products continues to grow, driving the vigorous development of the entire pharmaceutical industry, attracting many pharmaceutical companies and cross-border companies to deploy in this track
.
In 2019, the scale of China's medical beauty market has reached 176.
9 billion yuan, and it is expected to reach 184.
6 billion in 2021
.
For another example, in the field of ophthalmic diseases, if some non-blinding eye diseases are not treated in time, there will be a variety of serious complications and the risk of blindness
.
At present, the intervention of ophthalmic diseases has attracted more and more attention, which has also brought growth opportunities to the related ophthalmic treatment, drugs, devices, and service markets
.
Taking orthokeratology lenses as an example, this is a method of myopia control.
At present, the market penetration rate of orthokeratology lenses is still relatively low, so the market space is broad.
The industry expects that the market is expected to maintain a rapid growth trend. .
On the other hand, Chinese pharmaceutical and biological enterprises have begun to show strong competitive advantages in different subdivisions, and the trend of subdivision is becoming more and more obvious
.
For example, Kangtai Bio's performance on the vaccine track has attracted much market attention
.
According to reports, the advantages of the company's product line are reflected in the rich variety and excellent structure of vaccine products.
The products cover first-class vaccines and second-class vaccines.
There are more than 20 research pipelines, and 4 vaccines have been launched, especially genetically engineered vaccines (hepatitis B vaccine) and The combination vaccine (quadruple vaccine) has a high technical content, which is in line with the future development trend of the vaccine industry and has a very broad development prospect
.
For another example, Innovent's preemptive layout and achievements on the PD-1 track have also become the focus of the industry
.
Sintilimab successfully entered the National Medical Insurance Catalog in November 2019, and new indications have been continuously included
.
On December 3, 2021, Innovent announced that all approved indications of sintilimab have passed medical insurance negotiation and were successfully included in the new version of the National Medical Insurance List Category
B.
From the perspective of sales, the financial report for the first half of 2021 shows that the sales of Sintilimab of Innovent Biology in the first half of the year reached 1.
4 billion yuan; in the third quarter of 2021, the sales of sintilimab were about 800 million yuan
.
According to Eli Lilly, the sales of sintilimab in the first three quarters were about 2.
17 billion yuan, approaching the annual sales of 2020
.
.
In the long run, medicine is just in demand.
With the increase in per capita disposable income and the continuous upgrading of consumption, the pharmaceutical sector still has good growth potential, so it is also favored by many fund managers
.
From the perspective of trends, some pharmaceutical researchers said that the pharmaceutical and biological industry is gradually showing two major directions of diversification and segmentation
.
On the one hand, with the improvement of people's living standards, people's demand for different products in the field of pharmaceutical consumption is also increasing, making the pharmaceutical and biological industry track gradually diversified
.
For example, emerging tracks such as early intervention in diabetes, medical and cosmetic products, and intervention in ophthalmic diseases have emerged
.
China is a big country with diabetes, with a huge number of patients, up to over 100 million
.
With the enhancement of people's health awareness, they have gradually realized that diabetes prevention is more important than treatment.
On the basis of life>
.
In this context, patients are also actively seeking help and implementing diabetes management, which has driven the continuous expansion of the domestic diabetes management market and attracted companies to continue to deploy
.
In the era of beauty economy, coupled with the improvement of people's living standards, the demand for medical beauty products continues to grow, driving the vigorous development of the entire pharmaceutical industry, attracting many pharmaceutical companies and cross-border companies to deploy in this track
.
In 2019, the scale of China's medical beauty market has reached 176.
9 billion yuan, and it is expected to reach 184.
6 billion in 2021
.
For another example, in the field of ophthalmic diseases, if some non-blinding eye diseases are not treated in time, there will be a variety of serious complications and the risk of blindness
.
At present, the intervention of ophthalmic diseases has attracted more and more attention, which has also brought growth opportunities to the related ophthalmic treatment, drugs, devices, and service markets
.
Taking orthokeratology lenses as an example, this is a method of myopia control.
At present, the market penetration rate of orthokeratology lenses is still relatively low, so the market space is broad.
The industry expects that the market is expected to maintain a rapid growth trend. .
On the other hand, Chinese pharmaceutical and biological enterprises have begun to show strong competitive advantages in different subdivisions, and the trend of subdivision is becoming more and more obvious
.
For example, Kangtai Bio's performance on the vaccine track has attracted much market attention
.
According to reports, the advantages of the company's product line are reflected in the rich variety and excellent structure of vaccine products.
The products cover first-class vaccines and second-class vaccines.
There are more than 20 research pipelines, and 4 vaccines have been launched, especially genetically engineered vaccines (hepatitis B vaccine) and The combination vaccine (quadruple vaccine) has a high technical content, which is in line with the future development trend of the vaccine industry and has a very broad development prospect
.
For another example, Innovent's preemptive layout and achievements on the PD-1 track have also become the focus of the industry
.
Sintilimab successfully entered the National Medical Insurance Catalog in November 2019, and new indications have been continuously included
.
On December 3, 2021, Innovent announced that all approved indications of sintilimab have passed medical insurance negotiation and were successfully included in the new version of the National Medical Insurance List Category
B.
From the perspective of sales, the financial report for the first half of 2021 shows that the sales of Sintilimab of Innovent Biology in the first half of the year reached 1.
4 billion yuan; in the third quarter of 2021, the sales of sintilimab were about 800 million yuan
.
According to Eli Lilly, the sales of sintilimab in the first three quarters were about 2.
17 billion yuan, approaching the annual sales of 2020
.
